Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to refle
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
2. Dendreon Announces Pricing of Common Stock Offering
3. Dendreon Appoints Hans Bishop as Chief Operating Officer
4. Dendreon Announces Proposed Public Offering of Common Stock
5. Dendreon Receives FDA Acknowledgement of Complete Response
6. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
7. Dendreon Completes Submission of Biologics License Application for PROVENGE
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 27, 2010, after the market ... call at 5:00 p.m. ET, which will be open to ... the company will review the financial results and discuss other ...
... and NEW YORK, Oct. 20 ACCESS ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has submitted additional ... formulations of many global top-100 injectable drugs, as a ...
Cached Biology Technology:Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
(Date:7/9/2014)... an economy driven by methane, the primary component of natural ... production boom. It has poised the country as a top ... over just how climate-friendly it is, according to an article ... news magazine of the American Chemical Society. , In the ... when burned as a fuel to produce electricity, methane emits ...
(Date:7/9/2014)... at the NIH,s National Center for Advancing ... treat sickle cell disease has been acquired ... candidate, Aes-103, is the first specifically developed ... sickle cell disease. Baxter now will advance ... approval and commercialization. , Sickle cell disease ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... 5, 2008 Scientists report online this week in ... of specialized gut immune cells to a gene associated ... inflammatory bowel disorder. The link to immune cells ... St. Louis because they and others believe Crohn,s disease ...
... found the key to engineering plants capable of thriving ... report published online on October 2nd in Current ... that is generally plentiful in the earth,s crustcauses particular ... where acidic environments turn the metal into a form ...
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
Cached Biology News:Form of Crohn's disease traced to disabled gut cells 2How to build crops that can beat aluminum's toxic effects 2Reproducing early and often is the key to rapid evolution in plants 2
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: